Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation
Articles > Article · 2018
Authors: Sinem Yaprak KARAVANA, ZEYNEP ŞENYİĞİT, ÇAĞRI ÇALIŞKAN, Gülnur SEVİN, Derya İLEM ÖZDEMİR, YALÇIN ERZURUMLU, Sait ŞEN, ESRA BALOĞLU
DRUG DESIGN DEVELOPMENT AND THERAPY, Journal Indexed in SCI Expanded, International, 2018, vol Volume 12, pp 1959-1975
DOI: 10.2147/dddt.s164704
Summary
Introduction: Bladder cancer is responsible for more than 130,000 deaths annually worldwide. Intravesical delivery of chemotherapeutic agents provides effective drug localization to the target area to reduce toxicity and increase efficacy. This study aimed to develop ail intravesical delivery system of gemcitabine HC1 (Gem-HCl) to provide a sustained-release profile, to prolong residence time, and to enhance its efficiency in the treatment of bladder cancer.